Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulator of the dopaminergic and glutamatergic systems, and a serotonin reuptake inhibitor. By targeting the serotonergic and dopaminergic systems, the drug appears to reduce agitation and minimize positive symptoms. Its additional actions on glutamatergic signaling are believed to help address both negative and cognitive schizophrenia symptoms.
Intra-Cellular Therapies licensed lumateperone from its original developer, Bristol-Myers Squibb, in 2005, and is now solely responsible for the drug’s development. In December 2015, the company announced the initiation of patient enrollment for its two Phase III trials in bipolar depression. Additional clinical programs with lumateperone include its Phase III development in schizophrenia and behavioral disturbances in dementia.
LIST OF FIGURES
9 Figure 1: Lumateperone for bipolar disorder – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary for lumateperone in bipolar disorder
11 Figure 3: Datamonitor Healthcare’s drug assessment summary for lumateperone in bipolar disorder
19 Figure 4: Lumateperone for schizophrenia – SWOT analysis
20 Figure 5: Datamonitor Healthcare’s drug assessment summary of lumateperone for schizophrenia
21 Figure 6: Datamonitor Healthcare’s drug assessment summary of lumateperone for schizophrenia
23 Figure 7: Lumateperone sales for schizophrenia in the US, 2017–26
LIST OF TABLES
6 Table 1: Lumateperone drug profile
7 Table 2: Lumateperone Phase III trials in bipolar disorder
14 Table 3: Lumateperone drug profile
16 Table 4: Lumateperone Phase II and Phase III data in schizophrenia
19 Table 5: Lumateperone other interim Phase II data in schizophrenia
23 Table 6: Lumateperone sales for schizophrenia in the US ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.